irinotecan has been researched along with Neuroectodermal Tumors, Primitive, Peripheral in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, S; Gu, J; Guo, W; Huang, Y; Ren, T; Sun, K; Sun, X; Tang, X; Xie, L; Xu, J; Yang, F; Yang, R | 1 |
| Meyers, PA; Slotkin, EK | 1 |
| Aliç, T; Hassa, E | 1 |
| André, N | 1 |
| Ahn, HS; Kang, HJ; Kim, H; Lee, JW; Park, JD; Park, KD; Shin, HY | 1 |
| Ardouin, P; Bénard, J; Bissery, MC; Boland, I; Bressac-de-Paillerets, B; Gouyette, A; Gyergyay, F; Morizet, J; Terrier-Lacombe, MJ; Vassal, G; Vénuat, AM | 1 |
1 review(s) available for irinotecan and Neuroectodermal Tumors, Primitive, Peripheral
| Article | Year |
|---|---|
Irinotecan dose schedule for the treatment of Ewing sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Humans; Irinotecan; Neoplasm Recurrence, Local; Neuroectodermal Tumors, Primitive, Peripheral; Sarcoma, Ewing; Temozolomide | 2023 |
5 other study(ies) available for irinotecan and Neuroectodermal Tumors, Primitive, Peripheral
| Article | Year |
|---|---|
Quality of life and Q-TWiST were not adversely affected in Ewing sarcoma patients treated with combined anlotinib, irinotecan, and vincristine: (Peking University People's Hospital Ewing sarcoma trial-02, PKUPH-EWS-02).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Disease Progression; Female; Humans; Indoles; Irinotecan; Male; Neuroectodermal Tumors, Primitive, Peripheral; Prospective Studies; Quality of Life; Quinolines; Sarcoma, Ewing; Treatment Outcome; Vincristine; Young Adult | 2021 |
Ewing sarcoma: what trends in recent works? A holistic analysis with global productivity: A cross-sectional study.
Topics: Child; Cross-Sectional Studies; Humans; Irinotecan; Neuroectodermal Tumors, Primitive, Peripheral; Sarcoma, Ewing; Temozolomide | 2022 |
Comment on: Irinotecan dose schedule for the treatment of Ewing sarcoma-protracted/metronomic schedule-wording matters!
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Humans; Irinotecan; Neuroectodermal Tumors, Primitive, Peripheral; Sarcoma, Ewing | 2023 |
Irinotecan, vincristine, cisplatin, cyclophosphamide, and etoposide for refractory or relapsed medulloblastoma/PNET in pediatric patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Male; Medulloblastoma; Neoplasm Recurrence, Local; Neuroectodermal Tumors, Primitive, Peripheral; Radiotherapy; Retrospective Studies; Salvage Therapy; Vincristine; Young Adult | 2013 |
Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Cisplatin; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Female; Humans; Irinotecan; Mice; Mice, Nude; Neuroblastoma; Neuroectodermal Tumors, Primitive; Neuroectodermal Tumors, Primitive, Peripheral; Paclitaxel; Thiotepa; Topoisomerase I Inhibitors; Transplantation, Heterologous | 1996 |